Finerenone

Unassigned

New Medicines

Treatment of diabetic kidney disease in patients with type 2 diabetes mellitus to reduce risk of cardiovascular mortality/morbidity and rate of progression of kidney disease

Information

New molecular entity
Bayer
Bayer

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase II Clinical Trials

Category

Mineralocorticoid receptor antagonist, blocks the deletorious effects of aldosterone [1]
Estimates for the prevalence of kidney disease as a result of diabetes vary from around 18% to over 30%. The proportion of people with diabetes with end stage renal disease is increasing. In 2008-9 figures of 1.3% and 0.5% were reported for type 1 and type 2 diabetes which would translate to approximately 2500 people with type 1 diabetes and 9000 people with type 2 diabetes who may require dialysis or kidney transplantation [2].
Treatment of diabetic kidney disease in patients with type 2 diabetes mellitus to reduce risk of cardiovascular mortality/morbidity and rate of progression of kidney disease
Oral

Trial or other data

Jan 20 · PIII FIGARO-DKD (NCT02545049) and FIDELIO-DKD (NCT02540993) trials are ongoing, with an estimated primary completion date of Apr 20 and Jun 21, respectively [6].